CARLSBAD, Calif., Jan. 27, 2022 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has completed its acquisition of Mesa Biotech, Inc., a privately held molecular diagnostics company, for approximately $450 million in cash. The acquisition, first announced in December 2021, expands Thermo Fisher's point-of-care molecular diagnostics offerings. Mesa Biotech's Accula™ Flu A/Flu B, RSV and SARS-CoV-2 tests have received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and deliver results in approximately 30 minutes. The tests run on the company's proprietary Accula System, a PCR-based, easy-to-use, rapid molecular diagnostic platform designed for point-of-care testing. "The addition of Mesa Biotech's innovative platform expands our value proposition in health care by providing rapid, highly accurate results at the point of care," said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. "This acquisition also underscores our commitment to expand access to quality diagnostic testing, which is more important than ever in the fight against COVID-19 and other infectious diseases." Mesa Biotech will become part of Thermo Fisher's Life Sciences Solutions Segment. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. Media Contact Information: Ron O'Brien Phone: 781-622-1242 E-mail: ron.obrien@thermofisher.com Investor Contact Information: Rafael Tejada Phone: 781-622-1356 E-mail: rafael.tejada@thermofisher.com